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Abstract
Objective
To report the prevalence and incidence of low-risk human papillomavirus infection (LR-
HPV) and anogenital warts (AGW) among women living with HIV (WLHIV) in Burkina Faso
(BF) and South Africa (SA), and to explore HIV-related factors associated with these
outcomes.
Methods
We enrolled 1238 WLHIV (BF = 615; SA = 623) aged 25–50 years and followed them at
three time points (6, 12 and 16 months) after enrolment. Presence of AGW was assessed
during gynaecological examination. Cervico-vaginal swabs for enrolment and month 16 fol-
low-up visits were tested for HPV infection by Inno-LiPA® genotyping. Logistic regression
was used to assess risk factors for prevalent infection or AGW. Cox regression was used to
assess risk factors for incident AGW.
Results
Women in SA were more likely than those in BF to have prevalent LR-HPV infection (BF:
27.1% vs. SA: 40.9%; p<0.001) and incident LR-HPV infection (BF: 25.8% vs. SA: 31.6%, p
= 0.05). Prevalence of persistent LR-HPV was similar in the two countries (BF: 33.3% vs.
SA: 30.4%; p = 0.54), as were prevalence and incidence of AGW (Prevalence: BF: 7.5% vs.
SA: 5.7%; p = 0.21; Incidence: BF: 2.47 vs. SA: 2.33 per 100 person-years; p = 0.41). HPV6
was associated with incident AGW (BF: adjusted Hazard Ratio (aHR) = 4.88; 95%CI: 1.36–
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17.45; SA: aHR = 5.02; 95%CI: 1.40–17.99). Prevalent LR-HPV (BF: adjusted Odds Ratio
[aOR = 1.86]; 95%CI: 1.01–3.41; SA: aOR = 1.75; 95%CI: 0.88–3.48); persistent LR-HPV
(BF: aOR = 1.92; 95%CI: 0.44–8.44; SA: aOR = 2.81; 95%CI: 1.07–7.41) and prevalent
AGW (BF: aOR = 1.53; 95%CI: 0.61–3.87; SA: aOR = 4.11; 95%CI: 1.20–14.10) were each
associated with low CD4+ counts (i.e. <200 vs. >500 cells/μL). Duration of ART and HIV
plasma viral load were not associated with any LR-HPV infection or AGW outcomes.
Conclusion
LR-HPV infection and AGW are common in WLHIV in sub-Saharan Africa. Type-specific
HPV vaccines and effective ART with immunological reconstitution could reduce the burden
of AGW in this population.
Introduction
Anogenital human papillomavirus (HPV) infection is the most frequent sexually transmitted
infection (STI) globally.[1] Low Risk (LR) HPV types 6 and 11 are the predominant causes of
anogenital warts (AGW), a source of psychosocial distress,[2] and physical discomfort (includ-
ing bleeding and itching).[3] Approximately 25% of AGW spontaneously regress,[3] but recur-
rence is common, resulting in high medical costs from repeated treatment.[4]
There is little literature on the epidemiology of LR-HPV infection and AGW in Sub-Saha-
ran Africa. Regional variations in LR-HPV prevalence varies from 2% in Western Africa, 4%
in Southern Africa and 8% in Eastern Africa.[5] Similary, the prevalence of AGW ranges from
4–11% in Western, 2–14% in Southern and 3–11% in Eastern African regions.[6] The natural
history of HPV infection is altered by HIV infection, and HPV prevalence is higher where
HIV is more common or among individuals with HIV infection.[7] People living with HIV
who have AGW tend to experience florid and prolonged clinical manifestations of AGW
because of their impaired immune response.[8] Low CD4+ counts (<200 cells/μL) are associ-
ated with an increased risk of AGW.[9, 10] The impact of antiretroviral therapy (ART) on the
prevalence and incidence of AGW is unclear, with conflicting findings from different studies.
Some report that ART reduces incidence,[10] while other studies have shown that it does not
reduce incidence.[7, 11]
Three vaccines against HPV have been licensed,[12] two of which (quadrivalent and nona-
valent) have activity against HPV types 6 and 11 that cause 90% of AGW.[13, 14] These vac-
cines have been steadily introduced into national immunization programmes in both high and
low and middle income countries (LMIC), although the pace of introduction has been slower
in LMIC.[15] Data from countries which have included the quadrivalent vaccine (against
HPV6/11/16/18 types) in their vaccination programme show significant declines in the num-
ber of cases of AGW among vaccinated women and some herd-immunity effect in unvacci-
nated heterosexual men.[16] Decisions about which vaccine to include in a vaccination
programme are driven by cost-effectiveness considerations. Since a high-burden of AGW is
associated with significant costs to the health system in LMIC and this is worsened by high
HIV prevalence, data on the prevalence, incidence and correlates of LR-HPV and AGW is
important for informing vaccine programme decision-making and resource allocation.[12] To
address this question, we analysed data from a cohort of women living with HIV (WLHIV)
who participated in the HPV in Africa Research Partnership (HARP) study of cervical cancer
screening in Burkina Faso and South Africa.
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Materials and methods
Study design, population and sample collection
We conducted a prospective cohort study among WLHIV aged 25–50 years and residing in
Ouagadougou, Burkina Faso (BF) and Johannesburg, South Africa (SA) between December
2011 and October 2012. A full description of the study design and procedures has been pub-
lished elsewhere.[17] Briefly, enrolled participants were followed-up every 6 months up to 18
months. Data on clinical, socio-demographic and behavioural characteristics were collected by
interviewer-administered questionnaire at each visit. The presence of AGW was assessed at
enrolment and months 6, 12 and endline by trained nurse midwives during standardised pel-
vic examination. Cervical samples were collected using a Digene cervical sampler (Qiagen,
Courtaboeuf, France) for HPV-DNA testing and genotyping, a swab from the ecto/endocervix
to detect cervical sexually transmitted infections (STIs) by molecular methods and a vaginal
smear to diagnose bacterial vaginosis and Candida albicans by Gram stain at both enrolment
and endline visits. Blood samples were collected at enrolment to confirm HIV-1 serostatus,
perform Herpes Simplex Virus-2 (HSV-2) and syphilis serologies as well as obtain baseline
HIV-1 plasma viral load (PVL) measurement and CD4+ T-lymphocytes counts. The monitor-
ing of CD4+ counts was done at subsequent 6-monthly visits.
Laboratory methods
HIV-1 serostatus was diagnosed using two rapid tests according to national guidelines.[18, 19]
Testing for CD4+ cells was performed using FACScount (Becton-Dickinson, NJ). Plasma
HIV-1 RNA was assessed using real-time PCR (Abbott RT HIV-1) in BF and COBAS Taqman
(Roche Diagnostics) in SA, with a lower limit of detection of 40 copies/ml in both countries.
Laboratories subscribed to international external quality assessment schemes such as the
UK-NEQAS for CD4+ counts[20] and QCMD for HIV-1 PVL testing.[21]
HSV-2 serology was performed using the Kalon1 gG2 ELISA (Kalon Diagnostics, UK)
and syphilis serology by a combination of a Treponema pallidum haemagglutination (TPHA)
and rapid plasma reagin (RPR; BioMe´rieux, Lyon, France in BF and Immutrep carbon antigen
RPR, Omega Diagnostics in SA). Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma
genitalium and Trichomonas vaginalis were detected using nucleic acid amplification tests, the
Sacace simplex assays (Sacace, Como, Italy) in BF and the APTIMA Combo (Gen-Probe, San
Diego, CA) in SA. The Nugent’s score was used for vaginal flora reading of Gram-stained vagi-
nal smears, with diagnosis of bacterial vaginosis made for scores7, and examined for pres-
ence of Candida.
HPV DNA testing and genotyping was performed at the virology laboratory of University
of Montpellier (UM) using INNO-LiPA HPV Genotyping Extra Assay (Innogenetics, Courta-
boeuf, France). The assay is based on the amplification of a 65-bp fragment in the L1 gene and
detects 28 HPV types, including all the high-risk or probable high-risk types (16, 18, 26, 31, 33,
35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, 82) as well as the following LR HPV genotypes (6,
11, 40, 43, 44, 54, 69/71, 70,74).[22]
Statistical analysis
Any LR-HPV type infection was defined as detection of1 of the 9 genotypes described
above. LR-HPV type-specific persistence was defined as being positive for the same type at
enrolment and endline. Type-specific LR-HPV incidence was defined as the proportion of
women who were negative for a specific LR type at enrolment and positive for that type at end-
line. Prevalent AGW were defined as the presence of clinically-defined condyloma acuminata
Low risk HPV infection and AGW in HIV-1 infection
PLOS ONE | https://doi.org/10.1371/journal.pone.0196018 May 1, 2018 3 / 15
at the enrolment visit. Incident AGW were defined as the first documented occurrence of con-
dyloma acuminata in a woman previously documented not to have AGW. Time to incident
AGW was calculated from date of enrolment visit to the date of first AGW detection.
Descriptive statistics were used to summarize the prevalence of any LR-HPV infection and
AGW. For bivariate analysis, socio-demographic, sexual behaviour, presence of other labora-
tory detected STI (as part of the screening process at enrolment), clinical signs and HIV-
related risk factors were chosen for assessment a priori as known correlates for HPV and
AGW acquisition. As LR-HPV prevalence was common, associations with exposure variables
were estimated from prevalence ratios obtained from logistic regression using marginal stan-
dardization to estimate prevalence ratios, and the delta method to estimate 95% confidence
intervals (CIs). Associations between LR-HPV persistence and exposure variables were esti-
mated with generalized estimating equations to account for multiple LR-HPV infection and
multiple infection states (persistence and clearance).[23] To explore associations of any
LR-HPV and AGW with HIV-related factors, pre-specified analyses included stratification by
site, ART use, duration on ART ( or >2 years), HIV-1 viral suppression (< or1000 copies/
ml) and CD4+ cell counts at enrolment. Logistic regression (Model 1) was used to identify
independent associations between any prevalent LR-HPV or AGW and HIV-related factors,
after adjustment for potential confounders (non HIV-related factors) that were associated with
the outcomes in bivariate analysis at p<0.10.[24] A second logistic regression model (Model 2)
adjusted for CD4+ cell count at enrolment in addition to factors adjusted for in Model 1 was
run to explore associations with ART duration and HIV-1 viral suppression. Cox regression
was performed to analyse predictors of incident AGW, with and without adjustment for
potential confounders using the same model-building approach as described above under
logistic regression. Data were analysed using Stata version 14 (Stata Statistical Software, Col-
lege Station. TX: Stata Corporation).
Ethics statement
Study protocols were approved by the Ministry of Health in Burkina Faso (no. 2012-12-089),
the University of the Witwatersrand in South Africa (no. 110707), and the London School of
Hygiene and Tropical Medicine (no. 7400). All participants provided written informed consent.
Results
Study population
Of the 1473 women screened, 1238 (615 in BF and 623 in SA) were enrolled. The median age of
participants was 36 (interquartile range [IQR], 31–42) years in BF and 34 (IQR, 30–40) years in
SA. At enrolment, two-thirds of the participants were on ART (BF: 68.6% in BF; 65.2% in SA)
and this is because enrolment was stratified in the ratio of 2 ART users: 1 non-ART user. In BF,
the median CD4+ count was 417 (IQR, 315–606) cells/μL among ART-naive participants and 446
(IQR, 309–600) cells/μL among those on ART. In SA, the median CD4+ count was 448 (IQR,
353–614) cells/μL among ART-naive and 420 (IQR, 279–567) cells/μL among those on ART. A
more detailed description of study participants has been published elsewhere.[17]
Prevalence and correlates of LR-HPV infection
Almost all participants (n = 1215; 98.1%) had valid HPV genotyping results [BF = 594 (96.6%);
SA = 621 (99.7%)]. The prevalence of any LR-HPV was lower in BF (27.1%) than in SA
(40.9%) (p<0.001), as were the prevalence of the following LR types: 11 (1.5% vs. 5.3%,
p<0.001), 44 (7.7% vs. 11.6%, p = 0.02), 70 (4.0% vs. 8.9%, p = 0.001) and 74 (6.2% vs. 10.0%,
Low risk HPV infection and AGW in HIV-1 infection
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p = 0.02). Type 6 prevalence was similar in both countries (BF 5.7% vs. SA 5.3%). Type 44 was
the most prevalent LR-HPV type, for both countries (Fig 1A). In both countries, LR-HPV preva-
lence was lower among women who have had pregnancies compared to those who have been
never pregnant (BF: adjusted Prevalence Ratio (aPR) = 0.54; 95%CI: 0.29–0.99 vs. SA: aPR =
0.62; 95%CI: 0.44–0.89). In BF alcohol use (aPR = 1.41; 95%CI: 1.01–1.97) and self-reported con-
sistent condom use (aPR = 1.93; 95%CI: 1.07–3.47) were associated with higher LR-HPV preva-
lence. In SA LR-HPV prevalence was higher among women without a regular sexual partner
compared to those with a regular partner (aPR = 2.39; 95%CI: 1.37–4.19) (Table 1).
Associations between prevalent LR-HPV infection and HIV-related factors
Of the 1215 women with valid HPV results, 32 (2.6%) reported that they were not on ART at
enrolment despite undetectable HIV-1 PVL (BF = 24; SA = 8). Given the uncertainty of their
ART status, these women were excluded from HIV-related factors analyses. Further analyses
were conducted on the remaining 1183 participants (BF = 570; SA = 613) to determine the
effect of HIV-related factors on any LR-HPV prevalence (Table 2). In both countries, LR-HPV
prevalence was higher among women with a low CD4+ count (<200 cells/μL vs. >500 cells/
μL; Model 1 BF: adjusted Odds Ratio (aOR) = 1.37; 95%CI: 1.13–1.65 vs. Model 1 SA: aOR =
1.15; 95%CI: 0.99–1.33) (Table 2). Among ART users, a low CD4+ count was also associated
with a higher risk of prevalent LR-HPV infection (Model 1 BF: aOR = 1.41; 95%CI: 0.89–2.24
vs. Model 1 SA: aOR = 1.58; 95%CI: 1.06–2.34). The duration on ART (i.e. >2 years vs.2
years on ART) and HIV-1 PVL at enrolment were not significantly associated with prevalent
LR-HPV infection (Table 2).
Incidence and persistence of LR-HPV infection and effect of HIV-related
factors
Overall, 963/1238 (77.8%) WLHIV attended the endline visit at a median 16 (IQR, 15.6–16.8)
months and the majority (922) had HPV-genotyping results at both enrolment and endline
(BF = 476; SA = 446). Of these, 264 (28.7%) had incident LR-HPV of any type during follow-
up. The incidence of any LR-HPV infection was lower in BF compared to SA (BF: 25.8% vs.
SA: 31.6%, p = 0.05). This was also true for most individual types (11, 54 and 74) with the
exception of types 44 (BF: 4.7% vs. SA: 0.9%, p = 0.01) and 69/71 (BF: 8.5% vs. SA: 4.5%,
p = 0.02) which were significantly higher in BF compared to SA (Fig 1B).
A third of WLHIV (310/922) were defined as having persistent LR-HPV infection; the total
number of persistent infections was 396 (BF = 156; SA = 240). The frequency of persistent
infection of any LR-HPV at endline was similar in both countries (BF: 33.3% vs. SA: 30.4%;
p = 0.54). Persistence for individual types was largely similar between the two countries (Fig
1C). A low CD4+ count (i.e. <200 cells/μL vs.>500 cells/μL) was associated with a higher like-
lihood of having persistent LR-HPV infection. The association was stronger among ART users
(Model 1 BF: aOR = 3.21; 95%CI: 0.90–11.40 vs. Model 1 SA: aOR = 3.33; 95%CI: 0.96–11.55).
The duration on ART at enrolment and HIV-1 PVL were not significantly associated with per-
sistent LR HPV infection (S1 Table).
Prevalent AGW and effect of prevalent LR-HPV infection and HIV-related
factors
Overall, 81 (6.7%) WLHIV had AGW detected at enrolment; the prevalence did not vary by
country (BF: 7.5% vs. SA: 5.7%; p = 0.21). In univariate analysis (data not shown), prevalent
AGW were associated with age, number of partners in the last 3 months before enrolment,
Low risk HPV infection and AGW in HIV-1 infection
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presence of genital ulcers for both countries and being HSV-2 seropositive in BF or having
bacterial vaginosis in SA. Infection with any LR-HPV type, multiple LR-HPV infections, and
infection with types 6 (Model 2 BF aOR = 3.14; 95%CI: 1.11–9.01 and SA aOR = 1.79; 95%CI:
0.49–6.51) and 11 (Model 2 BF aOR = 20.12; 95%CI: 4.06–99.71 and SA aOR = 7.90; 95%CI:
3.11–20.09) were significantly associated with prevalent AGW (Table 3). In BF, HPV type 44
infection (Model 2 aOR = 3.59; 95%CI: 1.53–8.39), was strongly associated with prevalent
AGW. Similary in SA, HPV type 74 infection (Model 2 aOR = 3.28; 95%CI: 1.35–7.98) was
Fig 1. Type specific LR-HPV infection. (A) Prevalence at enrolment. (B) Incidence over 16 months. (C) Persistence
over 16 months. Significantly different between the two countries (i.e. p-value<0.05). Persistence as a proportion of
those positive for that specific type at enrolment.
https://doi.org/10.1371/journal.pone.0196018.g001
Table 1. The prevalence and correlates of LR-HPVa infection among 594 WLHIV in BF and 621 in SA.
Burkina Faso, N = 594 South Africa, N = 621
LR positive Crude Multivariateb LR positive Crude Multivariateb
N n (%) PR (95% CI) aPR (95% CI) p-value N n (%) PR (95% CI) aPR (95% CI) p-value
Partner status
Single or unmarried 305 101 (33.2) 1 1 357 146 (40.9) 1 1
Married or cohabiting 289 60 (20.8) 0.62 (0.47–0.82) 0.62 (0.33–1.19) 0.15 264 108 (40.9) 1.00 (0.83–1.21) 1.26 (0.69–2.32) 0.45
Alcohol use
Never 395 94 (23.8) 1 1 432 179 (41.4) 1 1
Ever 199 67 (33.7) 1.41 (1.09–
1.84)
1.41 (1.01–
1.97)
0.05 189 75 (39.7) 0.96 (0.78–1.18) 1.03 (0.80–1.33) 0.81
Number of pregnancies
0 24 11 (45.8) 1 1 31 18 (58.1) 1 1
1–2 200 63 (31.5) 0.69 (0.43–1.11) 0.76 (0.41–1.40) 0.38 329 136 (41.3) 0.71 (0.51–
0.99)
0.64 (0.46–
0.90)
0.01
3–4 370 87 (23.5) 0.51 (0.32–
0.82)
0.54 (0.29–
0.99)
0.05 261 100 (38.3) 0.66 (0.47–
0.92)
0.62 (0.44–
0.89)
0.01
Condom use
Never 68 10 (14.7) 1 1 31 11 (35.5) 1 1
Sometimes 70 10 (14.3) 0.97 (0.43–2.18) 0.82 (0.38–1.76) 0.61 172 63 (36.6) 1.03 (0.62–1.73) 1.26 (0.70–2.29) 0.44
Always 162 63 (38.9) 2.64 (1.45–
4.84)
1.93 (1.07–
3.47)
0.03 303 133 (43.9) 1.24 (0.76–2.02) 1.35 (0.76–2.40) 0.31
Currently has regular sexual
partner
Yes, cohabiting 196 42 (21.4) 1 1 258 105 (40.7) 1 1
Yes, non-cohabiting 105 40 (38.1) 1.78 (1.24–2.56) 0.83 (0.22–3.12) 0.79 243 99 (40.7) 1.00 (0.81–1.24) 1.35 (0.73–2.52) 0.34
No 72 21 (29.2) 1.36 (0.87–2.14) - 11 8 (72.7) 1.79 (1.21–
2.64)
2.39 (1.37–
4.19)
0.01
Lifetime number of sex partners
1 138 28 (20.3) 1 1 17 10 (58.8) 1 1
2–4 394 109 (27.7) 1.36 (0.94–1.97) 0.97 (0.60–1.57) 0.92 283 109 (38.5) 0.65 (0.43–
1.00)
0.61 (0.39–
0.94)
0.03
5+ 62 24 (38.7) 1.91 (1.21–3.01) 0.70 (0.34–1.44) 0.34 227 98 (43.2) 0.73 (0.48–1.12) 0.65 (0.41–1.01) 0.06
Candida albicans
No 491 141 (28.7) 1 1 558 223 (40.0) 1 1
Yes 83 14 (16.9) 0.59 (0.36–0.97) 0.50 (0.24–1.03) 0.60 52 25 (48.1) 1.20 (0.89–1.63) 1.14 (0.80–1.62) 0.47
a: LR-HPV = HPV6/11/40/43/44/54/70/69/71/74
b: Adjusted Prevalence Ratio (aPR) from logistic regression using marginal standardisation
All factors with p<0.05 are in bold
https://doi.org/10.1371/journal.pone.0196018.t001
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also significantly associated with prevalent AGW. AGW prevalence was higher among those
with low CD4+ counts (i.e. <200 cells/μL vs. >500 cells/μL), particularly in SA among all
women (aOR = 4.11; 95%CI: 1.20–14.10) and among ART users only (aOR = 3.93; 95%CI:
1.01–15.28). AGW prevalence was higher among those who had been on ART for two years or
less compared to those on ART for more than two years at enrolment in both BF (Model 1
aOR = 1.78; 95%CI: 0.87–3.64) and SA (Model 1 aOR = 1.88; 95%CI: 0.80–4.38), although the
association was less pronounced when adjusted for CD4+ count (Table 3).
AGW incidence and association with LR HPV infection and HIV-related
factors
A total of 32 new AGW events (BF = 16; SA = 16) were recorded for the 992 (BF = 468;
SA = 524) WLHIV who were followed up for a total of 1390 person-years. The overall AGW
Table 2. Associations between prevalent LR-HPVa and HIV-related factors among 570 WLHIV in BF and 613 in SA.
Burkina Fasob South Africac
N = 570d N = 613d
Description N n (%) Model 1 Model 2 N n (%) Model 1 Model 2
aOR (95% CI) aOR (95% CI) aOR (95% CI) aOR (95% CI
ART >2 years 194 52 (26.8) 1.00 1.00 225 84 (37.3) 1.00 1.00
ART Status ART2 years 218 67 (30.7) 1.24 (0.92–1.67) 1.19 (0.88–1.60) 179 84 (46.9) 1.22 (0.94–1.57) 1.15 (0.87–1.50)
ART-naive 158 36 (22.8) 0.87 (0.60–1.26) 0.82 (0.57–1.18) 209 83 (39.7) 1.11 (0.87–1.43) 1.11 (0.86–1.42)
>500 217 52 (24.0) 1.00 225 82 (36.4) 1.00
Enrolment 351–500 161 39 (24.2) 1.05 (0.87–1.25) 183 74 (40.4) 1.04 (0.92–1.17)
CD4+ count 201–350 125 40 (32.0) 1.11 (0.92–1.33) 148 66 (44.6) 1.09 (0.98–1.23)
(cells/μL) <200 66 24 (36.4) 1.37 (1.13–1.65) 57 29 (50.9) 1.15 (0.99–1.33)
Enrolment CD4+ count (cells/μL)
>500 52 10 (19.2) 1.00 87 35 (40.2) 1.00
ART-naive 351–500 42 7 (16.7) 0.86 (0.35–2.15) 70 24 (34.3) 1.10 (0.74–1.64)
201–350 45 12 (26.7) 1.37 (0.63–2.97) 46 22 (47.8) 1.12 (0.72–1.73)
<200 19 7 (36.8) 1.43 (0.55–3.71) 6 2 (33.3) 0.99 (0.35–2.77)
HIV-1 viral suppression
<1000 copies/ml 328 96 (29.3) 1.00 1.00 324 132 (40.7) 1.00 1.00
1000 copies/ml 55 18 (32.7) 1.13 (0.75–1.69) 0.98 (0.62–1.56) 76 35 (46.1) 1.14 (0.84–1.54) 1.09 (0.80–1.48)
HIV-1 viral detection
40 copies/ml 286 82 (28.7) 1.00 1.00 135 54 (40.0) 1.00 1.00
ART users >40 copies/ml 97 32 (33.0) 1.03 (0.85–1.24) 0.93 (0.75–1.16) 265 113 (42.6) 0.92 (0.81–1.03) 0.91 (0.81–1.03)
Enrolment CD4+ count (cells/μL)
>500 165 42 (25.5) 1.00 138 47 (34.1) 1.00
351–500 119 32 (26.9) 1.09 (0.74–1.60) 113 50 (44.3) 1.28 (0.91–1.80)
201–350 80 28 (35.0) 1.37 (0.93–2.02) 102 44 (43.1) 1.24 (0.87–1.76)
<200 47 17 (36.2) 1.41 (0.89–2.24) 51 27 (52.9) 1.58 (1.06–2.34)
aAny LR-HPV = HPV6/11/40/43/44/54/70/69/71/74; Adjusted Odds Ratio (aOR): Model 1
bIn Burkina Faso, associations with LR-HPV were adjusted for alcohol use, condom use and number of pregnancies
cIn SA, associations with LR-HPV were adjusted for regular sex partner, number of pregnancies and number of lifetime sex partners; For Model 2: same adjustment as
Model 1, in addition to enrolment CD4+ cell count
dOverall, 32 participants (BF: 24; SA: 8) reported that they were not on ART at enrolment despite undetectable HIV-1 viral load. Given the uncertainty of their ART
status, these were excluded from the analyses
All factors with p<0.05 are in bold.
https://doi.org/10.1371/journal.pone.0196018.t002
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Table 3. Effect of HIV-related factors and LR-HPV on AGW prevalence at enrolment among 572 WLHIV in BF and 613 in SA.
Burkina Fasoa South Africab
N = 572c N = 613c
Description N n (%) Model 1 aOR (95% CI) N n (%) Model 1 Model 2
aOR (95% CI) Model 2 aOR (95% CI) aOR (95% CI)
Any LR-HPVd 155 22
(14.2)
2.80 (1.48–5.27) 2.75 (1.44–5.23) 251 21 (8.4) 2.14 (1.05–4.36) 2.06 (1.01–4.21)
Multiple LR-HPV 34 9 (26.5) 6.50 (2.57–16.44) 5.97 (2.49–14.30) 65 10
(15.4)
4.65 (1.96–
11.37)
4.50 (1.81–
11.19)
HPV6 33 5 (15.2) 3.21 (1.12–9.15) 3.14 (1.11–9.01) 33 3 (9.1) 1.62 (0.45–5.82) 1.79 (0.49–6.51)
HPV11 9 5 (55.6) 21.54 (4.47–
103.82)
20.12 (4.06–
99.71)
33 9 (27.3) 7.32 (2.98–
18.00)
7.90 (3.11–
20.09)
HPV40 5 0 (0.0) 11 1 (9.1) 1.79 (0.21–15.00) 1.48 (0.17–12.75)
LR-HPV HPV43 7 2 (28.6) 4.08 (0.67–24.80) 4.03 (0.69–23.69) 3 0 (0.0)
HPV44 45 9 (20.0) 3.73 (1.61–8.67) 3.59 (1.53–8.39) 71 6 (8.5) 1.55 (0.60–4.00) 1.42 (0.54–3.72)
HPV54 14 1 (7.1) 0.72 (0.09–6.10) 0.60 (0.07–5.44) 20 3 (15.8) 3.60 (0.93–13.83) 3.47 (0.85–14.15)
HPV70 22 2 (9.1) 1.00 (0.22–4.63) 0.99 (0.21–4.57) 55 3 (5.5) 0.87 (0.25–3.02) 0.81 (0.23–2.84)
HPV69/71e 25 4 (16.0) 1.65 (0.50–5.49) 1.57 (0.45–5.43) 40 2 (5.o) 0.83 (0.18–3.81) 0.81 (0.17–3.804)
HPV74 35 5 (14.3) 2.10 (0.72–6.08) 2.19 (0.75–6.48) 61 8 (13.1) 3.34 (1.39–8.04) 3.28 (1.35–7.98)
ART >2 years 236 16 (6.8) 1 1 226 10 (4.4) 1 1
ART status ART2 years 173 20
(11.6)
1.78 (0.87–3.64) 1.78 (0.82–3.58) 178 15 (8.4) 1.88 (0.80–4.38) 1.41 (0.57–3.50)
ART-naive 163 9 (5.5) 0.63 (0.25–1.58) 0.62 (0.25–1.59) 209 10 (4.8) 0.83 (0.32–2.11) 0.80 (0.31–2.05)
>500 216 17 (7.9) 1 225 7 (3.1) 1
Enrolment 351–500 162 10 (6.2) 0.70 (0.31–1.61) 183 11 (6.0) 22.5 (0.83–6.09)
CD4
+ count
201–350 123 9 (7.3) 0.91 (0.39–2.14) 148 12 (8.1) 2.92 (1.09–7.79)
(cells/μL) <200 64 9 (14.1) 1.53 (0.61–3.87) 57 5 (8.8) 4.11 (1.20–
14.10)
Enrolment CD4+ count (cells/
μL)
>500 52 0 (0.0) 87 2 (2.3) 1
ART-naive 351–500 45 1 (2.2) 1 70 6 (8.6) 4.19 (0.77–22.80)
201–350 46 4 (8.7) 4.19 (0.45–39.00) 46 2 (4.4) 2.06 (0.27–15.54)
<200 19 4 (21.1) 11.7 (1.21–11.38) 6 0 (0.0)
HIV-1 viral suppression
<1000 copies/ml 357 34 (10) 1 1 328 19 (6) 1 1
1000 copies/ml 52 2 (4) 0.36 (0.08–1.61) 0.41 (0.09–1.92) 71 6 (9) 1.18 (0.44–3.17) 0.89 (0.31–2.52)
HIV-1 viral detection
40 copies/ml 315 25 (8) 1 1 139 7 (5) 1 1
ART users >40 copies/ml 94 11 (12) 1.36 (0.62–2.98) 1.60 (0.70–3.68) 260 18 (7) 1.15 (0.46–2.92) 1.09 (0.43–2.79)
Enrolment CD4+ count (cells/
μL)
>500 164 17 (10.4 1 138 5 (3.6) 1
351–500 117 9 (7.7) 0.72 (0.31–1.68) 113 5 (4.4) 1.30 (0.35–4.36)
201–350 77 5 (6.5) 0.60 (0.21–1.69) 102 10 (9.8) 2.66 (0.85–8.38)
(Continued)
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incidence was 2.30 per 100 person-years (BF: 2.47 vs. SA: 2.33 per 100 person-years, p = 0.41).
In univariate analysis (data not shown), incident AGW were associated with age for both
countries and number of partners in the last 3 months before enrolment in BF or having
mycoplasma genitalium in SA. Infection with any LR-HPV at enrolment was associated with
having an incident AGW; this association was statistically significant in BF (Model 1 adjusted
Hazard Ratio [aHR] = 5.78; 95%CI: 2.13–16.22) (Table 4). Prevalent type 6 infection at enrol-
ment was associated with an almost 5-fold higher odds of incident AGW in both BF (Model 1
aHR = 4.88; 95%CI: 1.36–17.45) and SA (Model 1 aHR = 5.02; 95%CI: 1.40–17.99). In BF,
prevalent HPV 74 infection was also significantly associated with incident AGW (Model 1
aHR = 6.02; 95%CI: 1.90–19.04). The incidence of AGW was higher in women with lower
CD4+ counts, with an inverse dose-response relationship in SA; but the duration on ART at
enrolment and HIV-1 PVL enrolment were not significantly associated with AGW incidence,
even after adjustment for CD4+ count (Model 2).
Discussion
We found that the prevalence and incidence of LR-HPV infection in this population were high
and consistent with other studies of WLHIV in sub-Saharan Africa.[7, 25, 26] We also found
that infections with types 6 and 11 were strongly associated with both prevalent and incident
(type 6 only) AGW, which confirms the literature.[7, 27] The prevalence of AGW in both
countries is similar to what has been reported among HIV-1 seropositive female sex workers
in Burkina Faso, [7] but the AGW incidence (BF = 2.47 and SA = 2.33 per 100 person-years)
was almost 3-fold lower than the 7.14 per 100 person-years reported by Low et al.,[7] possibly
owing to the repeated occupational exposure and lower proportion of WLHIV on ART (10%)
in that population.
We found that low enrolment CD4+ cell count was associated with a higher prevalence and
persistence of LR-HPV as well as a higher prevalence and incidence of AGW. This is consistent
with previous studies reporting CD4+ count as a strong predictor of HPV infection and AGW
development.[9, 10] A longer duration (>2 years) of ART was not protective per se against
prevalent LR-HPV infection, incident LR-HPV infection and incident AGW, confirming
other studies findings.[7, 11] This suggests that other co-factors such as adherence to ART,
Table 3. (Continued)
Burkina Fasoa South Africab
N = 572c N = 613c
Description N n (%) Model 1 aOR (95% CI) N n (%) Model 1 Model 2
aOR (95% CI) Model 2 aOR (95% CI) aOR (95% CI)
<200 45 5 (11.1) 1.08 (0.38–3.11) 51 5 (9.8) 3.93 (1.01–
15.28)
Adjusted Odds Ratio (aOR): For Model 1
aIn BF, associations with AGW were adjusted for age, number of partners in last 3 months, presence of genital ulcers and HSV2
bIn SA, associations with AGW were adjusted for age, number of partners in last 3 months, presence of genital ulcers and bacterial vaginosis; For Model 2: same
adjustment as Model 1, in addition to enrolment CD4+ count
cOverall 30 participants (BF: 22; SA: 8) reported that they were not on ART at enrolment despite undetectable HIV-1 viral load. Given the uncertainty of their ART
status, these were excluded from the analyses
dAny LR-HPV = HPV6/11/40/43/44/54/70/69/71/74
eINNOLiPA does not discriminate between HPV types 69 and 71
All factors with p<0.05 are in bold.
https://doi.org/10.1371/journal.pone.0196018.t003
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HIV-1 PVL suppression and immunological reconstitution (as measured by increases in CD4+
count) are also important for the control of HPV infection and progression to associated
disease.
Table 4. Effect of HIV-related factors and LR-HPV infection on incident AGW among 468 WLHIV in BF and 524 in SA.
Burkina Fasoa South Africab
Description Number of Model 1 Model 2 Number of Model 1 Model 2
events/Person aHR (95% CI) aHR (95% CI) events/Person aHR (95% CI) aHR (95% CI)
Years Years
LR HPV Any LR-HPVc 10/158 5.78 (2.13–16.22) 6.03 (2.15–16.89) 8/270 1.77 (0.66–4.74) 1.74 (0.64–4.72)
Multiple LR-HPV 1/20 7.38 (1.46–37.38) 6.56 (1.27–38.81) 2/64 2.22 (0.46–10.66) 2.09 (0.44–9.99)
HPV6 3/34 4.88 (1.36–17.45) 4.48 (1.25–16.09) 3/36 5.02 (1.40–17.99) 5.37 (1.47–19.70)
HPV11d 0/4 0/29
HPV40d 0/4 0/11
HPV43 1/7 6.63 (0.82–53.63) 6.80 (0.84–55.07) 0/4
HPV44 2/39 2.59 (0.59–11.44) 2.53 (0.55–11.51) 2/77 1.02 (0.23–4.52) 0.95 (0.21–4.23)
HPV54 1/18 2.13 (0.28–16.37) 4.67 (0.58–37.89) 1/19 2.72 (0.34–21.54) 3.36 (0.41–27.40)
HPV69/71e 0/8 2/40 3.41 (0.74–15.62) 3.38 (0.71–16.01)
HPV74 4/36 6.02 (1.90–19.04) 5.27 (1.64–17.00) 1/64 0.77 (0.10–5.88) 0.69 (0.09–5.33)
ART >2 years 8/293 1 1 7/264 1 1
ART status ART2 years 3/176 0.61 (0.16–2.32) 0.59 (0.15–2.31) 5/195 1.00 (0.32–3.16) 0.66 (0.19–2.33)
ART-naive 5/177 1.07 (0.31–3.72) 0.99 (0.28–3.48) 4/228 1.21 (0.35–4.24) 1.17 (0.32–4.26)
>500 4/253 1 4/260 1
Enrolment 351–500 8/192 2.44 (0.73–8.20) 5/209 1.35 (0.36–5.08)
CD4+ count 201–350 3/136 1.62 (0.36–7.26) 4/158 1.85 (0.46–7.47)
(cells/μL) <200 1/59 1.22 (0.14–10.88) 4/59 3.00 (0.66–13.61)
Enrolment CD4+ count (cells/μL)
>500 1/62 1 0/6 1
ART-naive 351–500 2/54 2.19 (0.19–25.36) 1/50 0.12 (0.01–2.64)
201–350 2/45 4.71 (0.41–54.47) 1/75 0.62 (0.05–7.57)
<200 0/15 2/97
HIV-1 viral suppression
<1000 copies/ml 9/411 1 1 11/374 1 1
1000 copies/ml 2/58 1.60 (0.34–7.54) 1.85 (0.31–10.90) 1/78 0.42 (0.05–3.40) 0.38 (0.05–3.08)
HIV-1 viral detection
40 copies/ml 7/366 1 1 4/153 1 1
ART users >40 copies/ml 4/103 1.97 (0.56–6.68) 2.32 (0.60–8.90) 8/297 0.98 (0.30–3.28) 1.03 (0.30–3.38)
Enrolment CD4+ count (cells/μL)
>500 3/191 1 2/63 1
351–500 6/138 2.54 (0.63–10.29) 4/134 2.45 (0.44–13.48)
201–350 1/90 0.81 (0.08–7.81) 3/107 2.80 (0.46–16.99)
<200 1/44 1.57 (0.16–15.12) 3/54 4.59 (0.76–27.89)
Adjusted Hazard Ratio (aHR): For Model 1
aIn Burkina Faso, associations with incident AGW were adjusted for age and number of sexual partners in the previous 3 months
bIn South Africa, associations with incident AGW were adjusted for age and mycoplasma genitalium; For Model 2: same adjustment as Model 1, in addition to
enrolment CD4+ count
c Any LR-HPV = HPV6/11/40/43/44/54/70/69/71/74
dThere were no observations for Type 11 and 40 in both countries
eINNOLiPA does not discriminate between HPV types 69 an d 71
All factors with p<0.05 are in bold.
https://doi.org/10.1371/journal.pone.0196018.t004
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We also found that, as reported in previous studies, non-HIV related factors such as alcohol
use, number of recent sexual partners, changes in vaginal flora and coinfection with other STIs
were significant co-factors for LR-HPV infection and AGW.[6, 7] In contrast to reports from
previous studies, we did not find significant association between smoking or hormonal contra-
ception with LR-HPV infection or AGW.[6, 28, 29] It was also surprising to note that LR-HPV
prevalence was high among women who reported consistent condom use. The reason why
infection prevalence was high among women who reported consistent condom use is not
known. However, this could be related to social desirability bias which meant that women
with high risk sexual behaviours reported high condom use.
Limitations of the study include the absence of HIV-1 PVL monitoring, in particular at
endline and the possible subjective nature of clinical examination for AGW detection without
histological confirmation leading to possible misclassification. Cervical LR-HPV infection
rather than vaginal/vulval LR-HPV infection was measured which would have been more
appropriate given the frequent external location of AGW. This can lead to difficulties in ascrib-
ing causality. However, cervical HPV infection has been used previously in determining asso-
ciations with AGW.[7] Despite these limitations, this study had a number of strengths,
including its longitudinal design, availability of AGW data at four time points and availability
of genotyping data at both enrolment and endline visits. More importantly, the study contrib-
utes data on the epidemiology of LR-HPV infection and AGW from two sub-Saharan African
countries with different HIV epidemics and this allows the findings to be extended to a range
of countries and settings in the region.
Conclusions
This study shows that WLHIV in sub-Saharan Africa are at high risk of LR-HPV infections
and AGW. AGW were associated with HPV 6/11 and these findings support the argument for
the use of quadri- or nano-valent HPV vaccines for the prevention of AGW among WLHIV.
Effective use of ART with immunological reconstitution could also help control the burden of
AGW among WLHIV in the region.
Supporting information
S1 Table. Effect of HIV-related factors on LR-HPV persistence, using infections as unit of
measure. Adjusted Odds Ratio (aOR) using generalised estimating equations: aIn BF, associa-
tions with LR-HPV were adjusted for alcohol use, condom use and number of pregnancies;
bIn SA, associations with LR-HPV were adjusted for number of regular sex partners, number
of pregnancies and number of lifetime sex partners; For Model 2: same adjustment as Model 1,
in addition to enrolment CD4+ count; c Of the 156 infections in Burkina Faso at enrolment
(Table 3), 5 were excluded from analysis as they were ART-naïve but with undetectable viral
load and similarly of the 240 infections at enrolment in South Africa (Table 3), 2 were excluded
from the analysis; dART use was defined as being on ART at both enrolment and endline; All
factors with p<0.05 are in bold.
(DOC)
S1 File. Full data set and codebook.
(XLS)
Acknowledgments
The research leading to these results has received funding from the European Commission
(EC) 7th Framework Programme under grant agreement No. HEALTH-2010-F2-265396.
Low risk HPV infection and AGW in HIV-1 infection
PLOS ONE | https://doi.org/10.1371/journal.pone.0196018 May 1, 2018 12 / 15
Contributing members of the HARP study group included: A. Chikandiwa, E. Cutler, S.
Delany-Moretlwe, L. Diep, C. Hwinya, D. A. Lewis, M.P. Magooa, V. Maseko, P. Michelow, B.
Muzah, T. Omar, A. Puren (Johannesburg, South Africa); F. Djigma, J. Drabo, O. Goumbri-
Lompo, D. Karambiri, N. Meda, B. Sawadogo, J. Simpore´, R. Sombie, A. Yonli, Z. Zamane, S
Zan (Ouagadougou, Burkina Faso); V. Costes, M.N. Didelot, S. Doutre, N. Leventoux, N.
Nagot, J. Ngou, M. Segondy (Montpellier, France); and A. Devine, C. Gilham, L. Gibson, H.
Kelly, R. Legood, P. Mayaud, H.A. Weiss (London, UK).
The HARP Study Group also wishes to thank its International Scientific Advisory Group
(ISAG) constituting of Prof. C. Lacey (Chair, University of York, UK), Prof. Y. Qiao (Chinese
Academy of Medical Sciences and Peking Union Medical College, Beijing, China), Prof. M.
Chirenje (University of Harare, Zimbabwe) and Prof. S. de Sanjose´ (Institut Catala d’Oncolo-
gia, Barcelona, Spain).
The HARP Study Group also wishes to thank Prof. W. Prendiville (International Federation
of Cervical Pathology and Colposcopy) and Dr A. Olaitan (Consultant Gynaecological
Oncologist at the University College London Hospital) who acted as external clinical advisors,
and Dr O. E Clavero (Institut Catala d’Oncologia (Barcelona, Spain) and H. Perocchia
(Department of Cytology and Anatomical Pathology, Gui de Chauliac Hospital, Montpellier,
France) who acted as independent readers for the Endpoint Committee.
Author Contributions
Conceptualization: Nicolas Meda, Helen A. Weiss, Michel Segondy, Philippe Mayaud, Sinead
Delany-Moretlwe.
Data curation: Admire Chikandiwa, Bernard Sawadogo, Lorna Gibson.
Formal analysis: Admire Chikandiwa, Helen Kelly, Pedro T. Pisa, Lorna Gibson, Marie-
Noelle Didelot.
Funding acquisition: Philippe Mayaud, Sinead Delany-Moretlwe.
Investigation: Admire Chikandiwa, Bernard Sawadogo, Jean Ngou, Marie-Noelle Didelot,
Sinead Delany-Moretlwe.
Methodology: Marie-Noelle Didelot, Nicolas Meda, Helen A. Weiss, Philippe Mayaud, Sinead
Delany-Moretlwe.
Project administration: Admire Chikandiwa, Helen Kelly, Bernard Sawadogo.
Resources: Nicolas Meda, Michel Segondy, Philippe Mayaud, Sinead Delany-Moretlwe.
Supervision: Nicolas Meda, Helen A. Weiss, Michel Segondy, Philippe Mayaud, Sinead
Delany-Moretlwe.
Validation: Helen A. Weiss.
Writing – original draft: Admire Chikandiwa.
Writing – review & editing: Helen Kelly, Pedro T. Pisa, Philippe Mayaud, Sinead Delany-
Moretlwe.
References
1. Schiffman M, Castle PE. Human papillomavirus: epidemiology and public health. Archives of pathology
& laboratory medicine. 2003; 127(8):930–4. Epub 2003/07/23. https://doi.org/10.1043/1543-2165
(2003)127<930:hpeaph>2.0.co;2 PMID: 12873163.
Low risk HPV infection and AGW in HIV-1 infection
PLOS ONE | https://doi.org/10.1371/journal.pone.0196018 May 1, 2018 13 / 15
2. Jeynes C, Chung MC, Challenor R. ’Shame on you’—the psychosocial impact of genital warts. Int J
STD AIDS. 2009; 20(8):557–60. Epub 2009/07/25. https://doi.org/10.1258/ijsa.2008.008412 PMID:
19625588.
3. Wiley DJ, Douglas J, Beutner K, Cox T, Fife K, Moscicki AB, et al. External genital warts: diagnosis,
treatment, and prevention. Clin Infect Dis. 2002; 35(Suppl 2):S210–24. Epub 15 Oct 2002. https://doi.
org/10.1086/342109 PMID: 12353208.
4. Insinga RP, Dasbach EJ, Elbasha EH. Assessing the annual economic burden of preventing and treat-
ing anogenital human papillomavirus-related disease in the US: analytic framework and review of the lit-
erature. Pharmacoeconomics. 2005; 23(11):1107–22. PMID: 16277547
5. De Vuyst H, Alemany L, Lacey C, Chibwesha CJ, Sahasrabuddhe V, Banura C, et al. The Burden of
Human Papillomavirus Infections and Related Diseases in Sub-Saharan Africa. Vaccine. 2013; 31,
Supplement 5:F32–F46. http://dx.doi.org/10.1016/j.vaccine.2012.07.092.
6. Banura C, Mirembe FM, Orem J, Mbonye AK, Kasasa S, Mbidde EK. Prevalence, incidence and risk
factors for anogenital warts in Sub Saharan Africa: a systematic review and meta analysis. Infect Agent
Cancer. 2013; 8(1):27. Epub 2013/07/12. https://doi.org/10.1186/1750-9378-8-27 PMID: 23842471;
PubMed Central PMCID: PMCPMC3712022.
7. Low AJ, Clayton T, Konate I, Nagot N, Ouedraogo A, Huet C, et al. Genital warts and infection with
human immunodeficiency virus in high-risk women in Burkina Faso: a longitudinal study. BMC Infect
Dis. 2011; 11(20):1471–2334.
8. Silverberg MJ, Ahdieh L, Munoz N, Anastos K, Burk RD, Cu-Uvin S. The Impact of HIV Infection and
Immunodeficiency on Human Papillomavirus Type 6 or 11 Infection and on Genital Warts. Sex Transm
Dis. 2002; 29:427–35. PMID: 12172526
9. Kavanaugh BE, Odem-Davis K, Jaoko W, Estambale B, Kiarie JN, Masese LN, et al. Prevalence and
Correlates of Genital Warts in Kenyan Female Sex Workers. Sexually Transmitted Diseases. 2012; 39
(11):902–5. doi: 10.1097/OLQ.0b013e318275ec7f. 00007435-201211000-00016. PMID: 23060082
10. Massad LS, Silverberg MJ, Springer G, Minkoff H, Hessol N, Palefsky JM, et al. Effect of antiretroviral
therapy on the incidence of genital warts and vulvar neoplasia among women with the human immuno-
deficiency virus. Am J Obstet Gynecol. 2004; 190(5):1241–8. https://doi.org/10.1016/j.ajog.2003.12.
037 PMID: 15167825
11. Dolev JC, Maurer T, Springer G, Glesby MJ, Minkoff H, Connell C, et al. Incidence and risk factors for
verrucae in women. Aids. 2008; 22. https://doi.org/10.1097/QAD.0b013e3283021aa3 PMID: 18525267
12. WHO. Summary of the WHO Position Paper on Vaccines against Human Papillomavirus (HPV)2017 2
October 2017. Available from: http://www.who.int/immunization/policy/position_papers/pp_hpv_
may2017_summary.pdf?ua=1.
13. Joura EA, Giuliano AR, Iversen O-E, Bouchard C, Mao C, Mehlsen J, et al. A 9-Valent HPV Vaccine
against Infection and Intraepithelial Neoplasia in Women. New England Journal of Medicine. 2015; 372
(8):711–23. https://doi.org/10.1056/NEJMoa1405044 PMID: 25693011.
14. Garland SM, Kjaer SK, Munoz N, Block SL, Brown DR, DiNubile MJ, et al. Impact and Effectiveness of
the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Expe-
rience. Clin Infect Dis. 2016; 63(4):519–27. Epub 2016/05/28. https://doi.org/10.1093/cid/ciw354 PMID:
27230391; PubMed Central PMCID: PMCPMC4967609.
15. LaMontagne DS, Bloem PJN, Brotherton JML, Gallagher KE, Badiane O, Ndiaye C. Progress in HPV
vaccination in low- and lower-middle-income countries. Int J Gynaecol Obstet. 2017; 138 Suppl 1:7–14.
https://doi.org/10.1002/ijgo.12186 PMID: 28691329.
16. Drolet M, Be´nard E´ , Boily M-C, Ali H, Baandrup L, Bauer H, et al. Population-level impact and herd
effects following human papillomavirus vaccination programmes: a systematic review and meta-analy-
sis. The Lancet Infectious Diseases. 2015; 15(5):565–80. https://doi.org/10.1016/S1473-3099(14)
71073-4 PMID: 25744474
17. Kelly HA, Sawadogo B, Chikandiwa A, Segondy M, Gilham C, Lompo O, et al. Epidemiology of High-
risk Human Papillomavirus and Cervical Lesions in African women living with HIV/AIDS: Effect of Anti-
Retroviral Therapy. Aids. 2017; 31(2):273–85. Epub 2016/10/19. https://doi.org/10.1097/QAD.
0000000000001301 PMID: 27755107.
18. Department of Health RoSA. National consolidated guidelines for the prevention of mother-to-child
transmission of HIV (PMTCT) and the management of HIV in children, adolescents and adults http://
www.health.gov.za/2014
19. VIH/SIDA Mdlscmdlcl. Normes et protocoles de prise en charge medicale des personnes vivant avec le
VIH au Burkina Faso http://www.remed.org/recommandations_officielles_du_ministere_de_la_sante_
nov2008.pdf2008.
20. UK-NEQAS. Immune Monitoring Programme (Accredited) 2016. Available from: http://www.ukneqasli.
co.uk/eqa-pt-programme-information/flow-cytometry-programmes/immune-monitoring/.
Low risk HPV infection and AGW in HIV-1 infection
PLOS ONE | https://doi.org/10.1371/journal.pone.0196018 May 1, 2018 14 / 15
21. QCMD. Quality Control for Molecular Diagnostics 2016. Available from: http://www.qcmd.org/index.
php?pageId=3&pageVersion=EN.
22. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. A review of human carcino-
gens—Part B: biological agents. Lancet Oncol. 2009; 10(4):321–2. Epub 2009/04/08. PMID: 19350698.
23. Xue X, Gange SJ, Zhong Y, Burk RD, Minkoff H, Massad LS, et al. Marginal and mixed-effects models
in the analysis of human papillomavirus natural history data. Cancer Epidemiol Biomarkers Prev. 2010;
19(1):159–69. Epub 2010/01/09. https://doi.org/10.1158/1055-9965.EPI-09-0546 PMID: 20056635;
PubMed Central PMCID: PMCPMC2839537.
24. Bursac Z, Gauss CH, Williams DK, Hosmer DW. Purposeful selection of variables in logistic regression.
Source code for biology and medicine. 2008; 3:17. Epub 2008/12/18. https://doi.org/10.1186/1751-
0473-3-17 PMID: 19087314; PubMed Central PMCID: PMCPMC2633005.
25. Mbulawa ZZ, Marais DJ, Johnson LF, Boulle A, Coetzee D, Williamson AL. Influence of human immu-
nodeficiency virus and CD4 count on the prevalence of human papillomavirus in heterosexual couples.
J Gen Virol. 2010; 91(Pt 12):3023–31. Epub 2010/08/20. https://doi.org/10.1099/vir.0.020669-0 PMID:
20719990.
26. Djigma FW, Ouedraogo C, Karou DS, Sagna T, Bisseye C, Zeba M, et al. Prevalence and genotype
characterization of human papillomaviruses among HIV-seropositive in Ouagadougou, Burkina Faso.
Acta tropica. 2011; 117(3):202–6. Epub 2010/12/21. https://doi.org/10.1016/j.actatropica.2010.12.007
PMID: 21167118.
27. Dunne EF, Nielson CM, Stone KM, Markowitz LE, Giuliano AR. Prevalence of HPV infection among
men: A systematic review of the literature. J Infect Dis. 2006; 194(8):1044–57. Epub 2006/09/23.
https://doi.org/10.1086/507432 PMID: 16991079.
28. Mzarico E, Gomez-Roig MD, Guirado L, Lorente N, Gonzalez-Bosquet E. Relationship between smok-
ing, HPV infection, and risk of Cervical cancer. European journal of gynaecological oncology. 2015; 36
(6):677–80. Epub 2016/01/19. PMID: 26775350.
29. Ghanem KG, Datta SD, Unger ER, Hagensee M, Shlay JC, Kerndt P, et al. The association of current
hormonal contraceptive use with type-specific HPV detection. Sex Transm Infect. 2011; 87(5):385–8.
https://doi.org/10.1136/sextrans-2011-050005 PMID: 21772042; PubMed Central PMCID:
PMCPMC3512558.
Low risk HPV infection and AGW in HIV-1 infection
PLOS ONE | https://doi.org/10.1371/journal.pone.0196018 May 1, 2018 15 / 15
